NCT00440297View on ClinicalTrials.gov

Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)

PHASE3CompletedINTERVENTIONAL
Enrollment

277

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Hepatitis B Virus Infection
Interventions
BIOLOGICAL

Comparator: modified process hepatitis B vaccine

Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.

BIOLOGICAL

Comparator: ENGERIX-B™

ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00440297 - Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060) | Biotech Hunter | Biotech Hunter